Idelalisib, a selective inhibitor of phosphatidylinositol 3-kinase-δ, as therapy for previously treated indolent non-Hodgkin lymphoma
Work
Year: 2014
Type: article
Source: Blood
Institutions Sarah Cannon, University of Wisconsin Carbone Cancer Center, Cornell University, Harvard University, The Ohio State University +4 more
Cites: 32
Cited by: 206
Related to: 10
FWCI: 20
Citation percentile (by year/subfield): 92.89
Subfield: Genetics
Field: Medicine
Domain: Health Sciences
Sustainable Development Goal Good health and well-being
Open Access status: bronze